Skip to content

Clinical Efficacy of Prophylactic Intravenous Neostigmine and Atropine in Preventing Post-Dural Puncture Headache Among Parturient Undergoing Spinal Anesthesia for Cesarean Section: A Double-blind Randomized Placebo-controlled Trial

Clinical Efficacy of Prophylactic Intravenous Neostigmine and Atropine in Preventing Post-Dural Puncture Headache Among Parturient Undergoing Spinal Anesthesia for Cesarean Section: A Double-blind Randomized Placebo-controlled Trial

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06493838
Enrollment
180
Registered
2024-07-10
Start date
2024-07-15
Completion date
2025-01-16
Last updated
2024-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pain

Brief summary

Post dural puncture headache is a distressing issue, many measures tried to treat symptoms but few delt with prevention.

Interventions

DRUGintravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.

intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.

DRUGNeostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.

Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Parturient ladies * Age ranges from 18 to 35 years old. * ASA II with elective caesarean section under sub-arachnoid block

Exclusion criteria

* BMI \>35 * Refusal to participate * surgical complications necessitating a blood transfusion * Emergency caesarean section * the need for endotracheal intubation or vasopressors * any contraindication to regional anesthesia (such as a history of persistent cephalgia, convulsions, cerebrovascular events

Design outcomes

Primary

MeasureTime frameDescription
Incidence of patients with post dural puncture headachefirst 5 days post-partumNumber of patients develop post dural puncture headache

Secondary

MeasureTime frameDescription
onset and duration of post dural puncture headache5 days post partumTime when visual analogue scale score increase and duration until return to 0. Visual analogue scale score for pain assessment. from 0 to ten. 0= no pain 1-3= mild pain....4-6= moderate pain ... 7-10= severe pain
Analgesic request24 hours after operationFirst time to analgesic request from block
Severity of post dural puncture headachefirst 5 days post-partumVisual analogue scale score for pain assessment. from 0 to ten. 0= no pain 1-3= mild pain....4-6= moderate pain ... 7-10= severe pain
frequency of analgesic doses5 daysnumber of analgesic doses given to the patient
incidence of complications related to the procedure6 hours after procedurenumber of patients with adverse events as bradycardia, tachcardia, miosis,muscle cramps, twitches, colics, hypotension
Analgesc requirements2 days after operationTotal analgesic requirements

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026